Gilead Sciences (GILD) Tax Rate (2009 - 2026)
Gilead Sciences' (GILD) quarterly Tax Rate came in at 2.36% in Q2 2026, down 2163.0% on a YoY basis from 0.11% in Q2 2025, and down 110.89% quarter-over-quarter from 21.67% in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) Tax Rate (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Tax Rate for 18 consecutive years, with 2.36% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Tax Rate fell 2163.0% year-over-year to 2.36%; the trailing twelve-month figure through Jun 2026 stood at 48.08% (down 6044.0% YoY), and the FY2025 full-year result was 13.13%, down 1745.0% from the prior year.
- Tax Rate eased to 2.36% in Q2 2026 per GILD's latest filing, from 21.67% in the prior quarter.
- Across five years, Tax Rate topped out at 107.89% in Q1 2022 and bottomed at 31.07% in Q3 2024.
- Historically, Tax Rate has averaged 18.14% across 5 years, with a median of 19.43% in 2022.
- The sharpest annual moves came in 2022 and 2023: Tax Rate jumped 8395 bps in 2022, then tumbled 8359 bps in 2023.
- Over 5 years, Tax Rate stood at 19.6% in 2022, then fell by 27 bps to 14.34% in 2023, then gained by 24 bps to 17.77% in 2024, then slumped by 222 bps to 21.66% in 2025, then soared by 89 bps to 2.36% in 2026.
- According to Business Quant data, Tax Rate over the past three periods registered 2.36%, 21.67%, and 21.66% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 14.20% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -2.36% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.98% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 15.11% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -10.89% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 7.49% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 26.36% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.34% |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | -16.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.36% |
| Mar 31, 2026 | 21.67% |
| Dec 31, 2025 | -21.66% |
| Sep 30, 2025 | 16.18% |
| Jun 30, 2025 | 19.27% |
| Mar 31, 2025 | 20.25% |
| Dec 31, 2024 | 17.77% |
| Sep 30, 2024 | -31.07% |
| Jun 30, 2024 | 21.33% |
| Mar 31, 2024 | 7.02% |
| Dec 31, 2023 | 14.34% |
| Sep 30, 2023 | 6.30% |
| Jun 30, 2023 | 34.57% |
| Mar 31, 2023 | 24.31% |
| Dec 31, 2022 | 19.60% |
| Sep 30, 2022 | 26.56% |
| Jun 30, 2022 | 24.48% |
| Mar 31, 2022 | 107.89% |
| Dec 31, 2021 | 50.46% |
| Sep 30, 2021 | 24.78% |